Markets

Receptos, Inc. (RCPT) in Focus: Stock Jumps 5.2% - Tale of the Tape

Receptos, Inc. ( RCPT ) was a big mover last session, as the company saw its shares rise over 5% on the day. The upside came after the company announced that it has completed the enrolment of patients in the RADIANCE Phase III trial on ozanimod on patients suffering from relapsing multiple sclerosis. The news led to far more shares changing hands than in a normal session resulting in solid volume. This continues the recent uptrend for the company as the stock is now up 36.47% in the past one-month time frame.

None of the estimates for this medical drugs stock were revised over the past seven days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Receptos currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.

A better-ranked stock in the same industry is ArQule Inc. ( ARQL ), carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RECEPTOS INC (RCPT): Get Free Report

ARQULE INC (ARQL): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More